Who
Garry E. Menzel
Director
Company insider
Files Form 4 as: Director, Black Diamond Therapeutics; Director, Stoke Therapeutics; Director, Adaptimmune Therapeutics; President and CEO, Tcr2 Therapeutics; Senior Vice President, Finance, DaVita; COO & Executive VP, Finance, Regulus Therapeutics.
In numbers
- Trades disclosed
- 87
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $145K
- Companies
- 6
- Companies where not an officer
- 3
- First trade
- 11 Dec 2012
- Last trade
- 26 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 29 Jun 2026 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 26 Jun 2026filed 29 Jun 2026 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 12 Jun 2025filed 12 Jun 2025 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,550 at $0.00 | filing |
| 3 Jun 2025filed 4 Jun 2025 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,747 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —1,121,604 at $0.00 | filing |
| 6 Jun 2024filed 6 Jun 2024 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,550 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,639 at $0.00 | filing |
| 10 Jul 2023filed 10 Jul 2023 | Adaptimmune Therapeutics | SEC FORM 4 Sold | $43K47,702 at $0.91 | filing |
| 5 Jul 2023filed 5 Jul 2023 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —736,548 at $0.00 | filing |
| 5 Jul 2023filed 5 Jul 2023 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —1,251,966 at $0.00 | filing |
| 5 Jul 2023filed 5 Jul 2023 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —359,700 at $0.00 | filing |
| 5 Jul 2023filed 5 Jul 2023 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —3,568,026 at $0.00 | filing |
| 5 Jul 2023filed 5 Jul 2023 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —57,846 at $0.00 | filing |
| 5 Jul 2023filed 5 Jul 2023 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —2,715,816 at $0.00 | filing |
| 5 Jul 2023filed 5 Jul 2023 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —2,158,776 at $0.00 | filing |
| 3 Jul 2023filed 3 Jul 2023 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —981,463 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,441 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —138,031 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —433,037 at $0.00 | filing |
| 1 Jun 2023filed 1 Jun 2023 | Tcr2 Therapeuticsoption or derivative | SEC FORM 4 Code D | —305,800 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.